Invivyd IVVD 深 沪
等待开盘 10-02 09:30:00 美东时间
0.8165
-0.054
-6.16%
华盛通- 最 高0.898
- 今 开0.8653
- 成交量 545.98万股
- 最 低 0.8057
- 昨 收 0.8701
- 总市值 2.41亿
- 52周最高 3.0699
- 市盈率 静 --
- 换手率 1.85%
- 52周最低 0.5277
- 委 比 59.29%
- 总股本 2.95亿
- 历史最高 78.82
- 量 比 0.45
- 振 幅 10.61%
- 历史最低 0.3546
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine
VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and tolerability of an mRNA-based COVID-19 vaccine VYD2311 combined with an mRNA-based COVID-...
09-29 19:05
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
Invivyd's VYD2311 monoclonal antibody demonstrated superior safety and tolerability compared to an mRNA-based COVID-19 vaccine in the LIBERTY Phase 3 trial, with no interference with vaccine-induced neutralizing titers. The study showed that VYD2311 alone or combined with the vaccine significantly reduced adverse events and enhanced immune responses. Invivyd plans to submit a Biologics License Application (BLA) under the FDA's Accelerated Approva...
09-29 11:01
美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target
BTIG analyst Thomas Shrader reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
09-14 20:24
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. granted 255,000 stock options to six new non-executive employees on September 1, 2026, under its 2026 Inducement Plan. The options, exercisable at $0.8799 per share, vest over four years and have a 10-year term. Invivyd, a biopharmaceutical company focused on viral infectious diseases, aims to develop best-in-class antibodies.
09-03 11:01
Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026
Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026. At that time, Invivyd plans to either unblind the DECLARATION study in its entirety and submit a Biologics License Application (BLA) towards traditional product approval, or partially unblind the study (lea...
09-01 19:10
Invivyd Appoints Marc Elia As CEO
Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director Ian Sheffield appointed to Invivyd...
09-01 19:08
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Invivyd (NASDAQ:IVVD) with a Overweight and maintains $10 price target.
08-27 19:14
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. granted stock options to 10 new employees totaling 277,500 shares, priced at $0.535 per share, vesting over four years. The options, granted under the 2026 Inducement Plan, have a 10-year term. Invivyd is a biopharmaceutical company focused on developing antibodies against serious viral diseases, including SARS-CoV-2, with a proprietary technology platform.
08-04 11:01
